BFRI Biofrontera Inc.
USHealthcareAs of 2026-08-24
Why BFRI matters now
Biofrontera Inc. (BFRI) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.46 with -1.35% on the session and $18.7M in market capitalization; recent performance reads 1-month +22.46% and YTD +73.16%.
The latest financial table shown here is Q1 2026, with revenue of $10.1M, net income of $-4.8M, and EPS of $-0.41. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -73.7%.
The latest indexable market news headline is "Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Leffler Eugene Frederick filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.90
P/S
0.29
EV/EBITDA
-1.40
DCF Value
$-32.97
FCF Yield
-73.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
82.8%
Operating Margin
-20.6%
Net Margin
-25.7%
ROE
-476.7%
ROA
-44.7%
ROIC
-62.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $10.1M | $-4.8M | $-0.41 |
| Q4 2025 | $17.1M | $5.6M | $0.48 |
| FY 2025 | $41.7M | $-10.5M | $-0.90 |
| Q3 2025 | $7.0M | $-6.6M | $-0.62 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Exchange
—
Beta
0.85
Biofrontera Inc. is a biopharmaceutical enterprise dedicated to the marketing and distribution of pharmaceutical products within the United States, specifically targeting various dermatological conditions. The company's portfolio includes Ameluz, a prescribed medication designed for photodynamic therapy. This treatment, utilized in conjunction with its licensor's RhodoLED lamp series, addresses mild-to-moderate actinic keratosis on the face and scalp through both localized (lesion-directed) and broader area (field-directed) applications. Furthermore, Biofrontera offers Xepi, a prescription cream indicated for the treatment of impetigo. The firm was founded in 2015 and operates from its headquarters located in Woburn, Massachusetts.